Amcasertib 是一种cancer Stemness kinase抑制剂，抑制Nanog和其他癌症干细胞通路，具有潜在的抗癌活性。

Amcasertib is an orally administered investigational agent designed to inhibit cancer stem cell pathways via targeting stemness kinases.

Standard incubation mixtures (final volume of 0.20 mL) containe recombinant P450 (0.010 μM) in 50 mM potassium phosphate bu?er (pH 7.4) containing an NADPH-generating system (0.5 mm NADP+, 5 mM glucose 6-phosphate, 0.5 unit glucose 6-phosphate dehydrogenase/mL) and substrates (1±100 lM). For determination of CYP1A2, CYP2B6, CYP2E1 and CYP3A4 activities, 100 mM potassium phosphate buffer (pH 7.4) is used. When human liver microsomes are used as the enzyme source, 500, 25, 100 and 25 pmol totalP450 per mL are used for paclitaxel 6a-hydroxylation, S-warfarin 7-hydroxylation,S-mephenytoin 4′-hydroxylation and testosterone 6b-hydroxylation respectively.

1129403-56-0

C31H33N5O2S

539.7

安卡舍替;BBI503

DMSO:30 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years